MX389127B - Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas. - Google Patents
Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas.Info
- Publication number
- MX389127B MX389127B MX2014013586A MX2014013586A MX389127B MX 389127 B MX389127 B MX 389127B MX 2014013586 A MX2014013586 A MX 2014013586A MX 2014013586 A MX2014013586 A MX 2014013586A MX 389127 B MX389127 B MX 389127B
- Authority
- MX
- Mexico
- Prior art keywords
- lysin
- antibiotic
- coating composition
- positive bacteria
- coating
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 7
- 230000003115 biocidal effect Effects 0.000 title abstract 5
- 241000192125 Firmicutes Species 0.000 title abstract 3
- 239000004472 Lysine Substances 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 6
- 239000008199 coating composition Substances 0.000 abstract 4
- 238000000576 coating method Methods 0.000 abstract 4
- 239000000049 pigment Substances 0.000 abstract 4
- 239000006185 dispersion Substances 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 108010013198 Daptomycin Proteins 0.000 abstract 2
- -1 Streptococcal lysin Chemical compound 0.000 abstract 2
- 108010059993 Vancomycin Proteins 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 2
- 229960005484 daptomycin Drugs 0.000 abstract 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 2
- 229960003907 linezolid Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 abstract 2
- 229960001019 oxacillin Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 2
- 229960003165 vancomycin Drugs 0.000 abstract 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644944P | 2012-05-09 | 2012-05-09 | |
| US201261737239P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/040329 WO2013170015A1 (en) | 2012-05-09 | 2013-05-09 | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013586A MX2014013586A (es) | 2015-06-05 |
| MX389127B true MX389127B (es) | 2025-03-19 |
Family
ID=49551273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013586A MX389127B (es) | 2012-05-09 | 2013-05-09 | Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas. |
| MX2021011843A MX2021011843A (es) | 2012-05-09 | 2014-11-07 | Lisina de bacteriofago y combinaciones de antibioticos contra bacterias gram positivas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011843A MX2021011843A (es) | 2012-05-09 | 2014-11-07 | Lisina de bacteriofago y combinaciones de antibioticos contra bacterias gram positivas. |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10813983B2 (enExample) |
| EP (2) | EP2849782B1 (enExample) |
| JP (4) | JP6608697B2 (enExample) |
| KR (3) | KR102310387B1 (enExample) |
| CN (1) | CN104736172A (enExample) |
| AU (3) | AU2013259512B2 (enExample) |
| BR (1) | BR112014027842A2 (enExample) |
| CA (1) | CA2872902A1 (enExample) |
| DK (1) | DK2849782T3 (enExample) |
| ES (1) | ES2784136T3 (enExample) |
| HK (1) | HK1211484A1 (enExample) |
| IL (3) | IL308477A (enExample) |
| IN (1) | IN2014MN02437A (enExample) |
| MX (2) | MX389127B (enExample) |
| RU (2) | RU2018121290A (enExample) |
| WO (1) | WO2013170015A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013259427B2 (en) | 2012-05-09 | 2017-12-14 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
| KR102310387B1 (ko) | 2012-05-09 | 2021-10-13 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| KR102441211B1 (ko) | 2014-06-26 | 2022-09-07 | 더 락커펠러 유니버시티 | 아시네토박터 라이신 |
| JP2018509415A (ja) * | 2015-03-12 | 2018-04-05 | マイクレオス ヒューマン ヘルス ビー．ブイ．Ｍｉｃｒｅｏｓ Ｈｕｍａｎ Ｈｅａｌｔｈ Ｂ．Ｖ． | 細菌感染の治療方法 |
| MX2018003100A (es) | 2015-09-17 | 2019-04-15 | Contrafect Corp | Uso de lisina para restaurar/aumentar la actividad antibacteriana en presencia de agente tensoactivo pulmonar de antibioticos inhibidos en el mismo. |
| CN109152822B (zh) * | 2016-05-12 | 2023-12-05 | 抗非特公司 | 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法 |
| DK3641753T3 (da) | 2017-06-19 | 2022-12-12 | Univ Syddansk | Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner |
| EP3651739A4 (en) * | 2017-07-10 | 2021-04-07 | Contrafect Corporation | BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES |
| JP2021513865A (ja) * | 2018-02-26 | 2021-06-03 | コントラフェクト コーポレイション | 修飾ＰｌｙＳｓ２溶解素及びその使用 |
| CN116850269A (zh) * | 2018-06-22 | 2023-10-10 | 康特拉费克特公司 | 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感 |
| CN109668873B (zh) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | 一种活载体疫苗活性检测装置及其使用方法 |
| CN113677799A (zh) * | 2019-02-05 | 2021-11-19 | 伊兰科美国公司 | 一种遗传修饰乳酸杆菌及其应用 |
| EP3941504A4 (en) * | 2019-03-22 | 2022-12-07 | Contrafect Corporation | METHOD FOR TREATING INFECTIOUS ENDOCARDITIS |
| US20220193186A1 (en) * | 2019-04-11 | 2022-06-23 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| WO2021127452A1 (en) * | 2019-12-19 | 2021-06-24 | Georgia State University Research Foundation, Inc. | Compounds for the treatment of bacterial infections and potentiation of antibiotics |
| US20230277632A1 (en) * | 2020-05-19 | 2023-09-07 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| RU2755817C1 (ru) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ снижения грамположительной микрофлоры в кишечнике птицы |
| KR102528412B1 (ko) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
| WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
| CN115105491B (zh) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | 丝氨酸在制备抑制猪链球菌药物中的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988002781A1 (en) | 1986-10-08 | 1988-04-21 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| EP0895534A1 (en) * | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| MXPA01008701A (es) | 1999-02-25 | 2003-06-24 | New Horizons Diagnostics Inc | Un medio para el tratameinto profilactico y terapeutico de infecciones estreptococicas. |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| EP1501925A4 (en) | 2002-05-17 | 2006-10-25 | New Horizons Diagnostics Corp | IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| US7638600B2 (en) * | 2004-03-24 | 2009-12-29 | The Rockefeller University | Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores |
| US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| CA2620903A1 (en) | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
| WO2009029192A1 (en) | 2007-08-24 | 2009-03-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
| US8840900B2 (en) * | 2008-07-03 | 2014-09-23 | The Rockefeller University | Chimeric bacteriophage lysin with activity against Staphylococci bacteria |
| KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| CN103080307A (zh) | 2010-01-25 | 2013-05-01 | 美艾利尔斯卡保罗有限公司 | A25噬菌体溶解酶 |
| US20120271770A1 (en) * | 2011-04-20 | 2012-10-25 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
| WO2012145573A2 (en) | 2011-04-21 | 2012-10-26 | Universiteit Utrecht Holding Bv | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
| US9034322B2 (en) | 2011-04-21 | 2015-05-19 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| US9016640B2 (en) | 2011-04-22 | 2015-04-28 | Rks Design, Inc. | Instrument retention assembly |
| EP2702070B1 (en) | 2011-04-27 | 2015-09-30 | Lysando AG | New antimicrobial agents |
| AU2013259427B2 (en) * | 2012-05-09 | 2017-12-14 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
| KR102310387B1 (ko) | 2012-05-09 | 2021-10-13 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
-
2013
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/ko not_active Expired - Fee Related
- 2013-05-09 HK HK15112347.8A patent/HK1211484A1/xx unknown
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/zh active Pending
- 2013-05-09 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/ru unknown
- 2013-05-09 ES ES13787128T patent/ES2784136T3/es active Active
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/ja not_active Expired - Fee Related
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en not_active Ceased
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/ru active
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en not_active Ceased
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/ko not_active Ceased
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/pt not_active IP Right Cessation
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 MX MX2014013586A patent/MX389127B/es unknown
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/ko not_active Withdrawn
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 US US14/399,575 patent/US10813983B2/en not_active Expired - Fee Related
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/da active
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-06-04 US US13/909,618 patent/US9889181B2/en active Active
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/es unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en not_active Ceased
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/ja not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/ja active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389127B (es) | Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas. | |
| WO2016083798A8 (en) | Prevention and treatment of microbial infections | |
| UA107922C2 (en) | Pigment granules | |
| GB201013307D0 (en) | Anti-microbial metal organic framework | |
| EP4332217A3 (en) | Antibacterial phage, phage peptides and methods of use thereof | |
| EP3466885A4 (en) | OXIDE PARTICLES WITH CONTROLLED COLOR CHARACTERISTICS AND COATING COMPOSITION OR FILM-LIKE COMPOSITION WITH THESE OXIDE PARTICLES | |
| WO2012018242A3 (ko) | 탄소소재를 이용한 고효율 방열도료 조성물 | |
| MX2015000119A (es) | Recubrimientos elastoméricos con propiedades hidrofóbicas y/u oleofóbicas. | |
| WO2009126859A3 (en) | Natural ester, wax or oil treated pigment, process for production thereof, and cosmetic made therewith | |
| NZ591051A (en) | C7-fluoro substituted tetracycline compounds | |
| WO2017092920A3 (en) | Use of (hetero)polyoxometalates for simultaneously imparting antimicrobial properties to, and reducing the growth of a biofilm on a surface of a substrate in or on a home appliance | |
| MX2015001038A (es) | Copolimeros de polisiloxano. | |
| BR112017018187A2 (pt) | composições compreendendo combinações de ácidos orgânicos | |
| WO2010052190A3 (en) | Wound dressings | |
| WO2013188496A3 (en) | Corrosion resistant additive compositions and coating compositions employing the same | |
| BR112013001258A2 (pt) | processo para fornecer uma aparência antiga a um substrato, substrato, arranjo de 2 revestimentos, e, uso de pigmentos de efeito à base de perlita. | |
| PH12013502631B1 (en) | Formulation | |
| WO2014140846A3 (en) | Inorganic composite coatings comprising novel functionalized acrylics | |
| MX2017015212A (es) | Composicion de oxido revestido con oxido de silicio para revestimiento en la que se requiere resistencia a la intemperie, y metodo de fabricacion de la composicion para el revestimiento. | |
| EP4464750A3 (en) | Non-magnetizable effect pigments | |
| MX2019002340A (es) | Composiciones de revestimiento y revestimientos para ajustar la friccion. | |
| BR112019004399A2 (pt) | composição de revestimento em pó híbrida de poliéster e fluorocarbono e método de revestimento de substratos | |
| SA518391368B1 (ar) | طلاء متعدد الطبقات ذو تأثير مرئي | |
| EP3006434A4 (en) | Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes | |
| MX2015002311A (es) | Composicion de recubrimiento con dispersante funcionalizado con trisamina. |